3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Dermatologic
1
CNS
1
Conditions
Neoplasms
4
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Lymphoproliferative Disorders
2
Glioma
2
Melanoma
1
Locally Advanced Thyroid Gland Carcinoma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Interventions
entrectinib
2
atezolizumab
2
alectinib
2
venetoclax
1
pertuzumab
1
obinutuzumab
1
ibrutinib
1
etoposide phosphate
1
enzalutamide
1
cobimetinib
1
capmatinib
1
acalabrutinib
1
Vincristine
1
Vemurafenib
1
Trastuzumab
1
Specimen Handling
1
Rituximab
1
Radiotherapy
1
Prednisone
1
Positron-Emission Tomography
1
Nivolumab
1
Genetic Testing
1
Genetic Counseling
1
Follow-Up Studies
1
Etoposide
1
Doxorubicin
1
Cyclophosphamide
1
Chromatin Immunoprecipitation Sequencing
1
CA-4948
1
Biological Assay
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoproliferative Disorders
×
entrectinib
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled